Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients

Journal of Dermatological Science

Volumn 56, Issue 2, 2009, Pages 82-88

  Hickerson, Robyn P ^a   Leake, Devin ^b   Pho, Lana N ^c   Leachman, Sancy A ^c   Kaspar, Roger L ^a  

^a TransDerm Inc   (United States)

^b Thermo Fisher Scientific   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

mTOR inhibitor; Sirolimus; TOP mRNA; Translational regulation

Indexed keywords

AFINITOR; CYTOKERATIN 14; CYTOKERATIN 16; CYTOKERATIN 17; CYTOKERATIN 5; CYTOKERATIN 6; EVEROLIMUS; KERATIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN K6A; PROTEIN K6B; RAPAMYCIN; SMALL INTERFERING RNA; TEMSIROLIMUS; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ACNE; ADULT; ANOREXIA; APHTHOUS ULCER; ARTICLE; CASE REPORT; CLINICAL ASSESSMENT TOOL; CLINICAL EXAMINATION; CONGENITAL PACHYONYCHIA; DIARRHEA; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL CULTURE; KERATINOCYTE; PATIENT MONITORING; PHOTOGRAPHY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; REGULATORY SEQUENCE; SIGNAL TRANSDUCTION; SYMPTOMATOLOGY; THROMBOSIS; TRANSCRIPTION INITIATION SITE; TREATMENT OUTCOME; WESTERN BLOTTING;

5' UNTRANSLATED REGIONS; ADMINISTRATION, ORAL; BASE SEQUENCE; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; HUMANS; KERATIN-6; KERATINOCYTES; MOLECULAR SEQUENCE DATA; PACHYONYCHIA CONGENITA; PAIN; PAIN MEASUREMENT; PROTEIN KINASES; QUALITY OF LIFE; RNA 5' TERMINAL OLIGOPYRIMIDINE SEQUENCE; RNA INTERFERENCE; RNA, MESSENGER; SIROLIMUS; TIME FACTORS; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 70349987628     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2009.07.008     Document Type: Article

References (39)

1. Tyner A.L., and Fuchs E. Evidence for posttranscriptional regulation of the keratins expressed during hyperproliferation and malignant transformation in human epidermis. J Cell Biol 103 5 (1986) 1945-1955
2. Takahashi K., Paladini R.D., and Coulombe P.A. Cloning and characterization of multiple human genes and cDNAs encoding highly related type II keratin 6 isoforms. J Biol Chem 270 31 (1995) 18581-18592
3. Yamashita R., Suzuki Y., Takeuchi N., Wakaguri H., Ueda T., Sugano S., et al. Comprehensive detection of human terminal oligo-pyrimidine (TOP) genes and analysis of their characteristics. Nucleic Acids Res 36 11 (2008) 3707-3715
4. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev 18 16 (2004) 1926-1945
5. Meyuhas O., and Hornstein E. Translational control of TOP mRNAs. In: Sonenberg N., Hershey J.W.B., and Mathews M.B. (Eds). Translational control of gene expression (2000), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 671-693
6. Kaspar R.L., Kakegawa T., Cranston H., Morris D.R., and White M.W. A regulatory cis element and a specific binding factor involved in the mitogenic control of murine ribosomal protein L32 translation. J Biol Chem 267 1 (1992) 508-514
7. Avni D., Shama S., Loreni F., and Meyuhas O. Vertebrate mRNAs with a 5′-terminal pyrimidine tract are candidates for translational repression in quiescent cells: characterization of the translational cis-regulatory element. Mol Cell Biol 14 6 (1994) 3822-3833
8. Jefferies H.B., Reinhard C., Kozma S.C., and Thomas G. Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. Proc Natl Acad Sci USA 91 10 (1994) 4441-4445
9. Terada N., Patel H.R., Takase K., Kohno K., Nairn A.C., and Gelfand E.W. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc Natl Acad Sci USA 91 24 (1994) 11477-11481
10. Zhu J., Spencer E.D., and Kaspar R.L. Differential translation of TOP mRNAs in rapamycin-treated human B lymphocytes. Biochim Biophys Acta 1628 1 (2003) 50-55
11. Raught B., Gingras A.C., and Sonenberg N. The target of rapamycin (TOR) proteins. Proc Natl Acad Sci USA 98 13 (2001) 7037-7044
12. Kawasome H., Papst P., Webb S., Keller G.M., Johnson G.L., Gelfand E.W., et al. Targeted disruption of p70(s6k) defines its role in protein synthesis and rapamycin sensitivity. Proc Natl Acad Sci USA 95 9 (1998) 5033-5038
13. Jefferies H.B., Fumagalli S., Dennis P.B., Reinhard C., Pearson R.B., and Thomas G. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J 16 12 (1997) 3693-3704
14. Sonenberg N. eIF4E, the mRNA cap-binding protein: from basic discovery to translational research. Biochem Cell Biol 86 2 (2008) 178-183
15. Smith F.J.D., Kaspar R.L., Schwartz M.E., McLean W.H.I., and Leachman S.A. Pachyonychia congenita. GeneReviews (2006). www.genetests.org/profiles/pc
16. Leachman S.A., Kaspar R.L., Fleckman P., Florell S.R., Smith F.J., McLean W.H., et al. Clinical and pathological features of pachyonychia congenita. J Invest Dermatol Symp Proc 10 1 (2005) 3-17
17. McLean W.H., Rugg E.L., Lunny D.P., Morley S.M., Lane E.B., Swensson O., et al. Keratin 16 and keratin 17 mutations cause pachyonychia congenita. Nat Genet 9 3 (1995) 273-278
18. Boukamp P., Petrussevska R.T., Breitkreutz D., Hornung J., Markham A., and Fusenig N.E. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106 3 (1988) 761-771
19. Hickerson R.P., Smith F.J., Reeves R.E., Contag C.H., Leake D., Leachman S.A., et al. Single-nucleotide-specific siRNA targeting in a dominant-negative skin model. J Invest Dermatol 128 3 (2008) 594-605
20. Zhu J., Hayakawa A., Kakegawa T., and Kaspar R.L. Binding of the La autoantigen to the 5′ untranslated region of a chimeric human translation elongation factor 1A reporter mRNA inhibits translation in vitro. Biochim Biophys Acta 1521 1-3 (2001) 19-29
21. Randle R.A., Raguz S., Higgins C.F., and Yague E. Role of the highly structured 5′-end region of MDR1 mRNA in P-glycoprotein expression. Biochem J 406 3 (2007) 445-455
22. Michlewski G., Sanford J.R., and Caceres J.F. The splicing factor SF2/ASF regulates translation initiation by enhancing phosphorylation of 4E-BP1. Mol Cell 30 2 (2008) 179-189
23. Wong P., and Coulombe P.A. Loss of keratin 6 (K6) proteins reveals a function for intermediate filaments during wound repair. J Cell Biol 163 2 (2003) 327-337
24. Smith F.J., Hickerson R.P., Sayers J.M., Reeves R.E., Contag C.H., Leake D., et al. Development of therapeutic siRNAs for pachyonychia congenita. J Invest Dermatol 128 1 (2008) 50-58
25. Wong P., Domergue R., and Coulombe P.A. Overcoming functional redundancy to elicit pachyonychia congenita-like nail lesions in transgenic mice. Mol Cell Biol 25 1 (2005) 197-205
26. PDF. Physicians' Desk Reference. 61 ed.; 2007.
27. Lewis V., and Finlay A.Y. 10 years experience of the Dermatology Life Quality Index (DLQI). J Invest Dermatol Symp Proc 9 2 (2004) 169-180
28. Finlay A.Y., and Khan G.K. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 19 3 (1994) 210-216
29. Mahe E., Morelon E., Lechaton S., Kreis H., De Prost Y., and Bodemer C. Sirolimus-induced onychopathy in renal transplant recipients. Ann Dermatol Venereol 133 6-7 (2006) 531-535
30. Leachman S.A., Hickerson R.P., Hull P.R., Smith F.J., Milstone L.M., Lane E.B., et al. Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. J Dermatol Sci 51 3 (2008) 151-157
31. Jimenez-Diaz L., Geranton S.M., Passmore G.M., Leith J.L., Fisher A.S., Berliocchi L., et al. Local translation in primary afferent fibers regulates nociception. PLoS ONE 3 4 (2008) e1961
32. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8 2 (2002) 128-135
33. Phung T.L., Ziv K., Dabydeen D., Eyiah-Mensah G., Riveros M., Perruzzi C., et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10 2 (2006) 159-170
34. Meric-Bernstam F., and Gonzalez-Angulo A.M. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27 13 (2009) 2278-2287
35. Ormerod A.D., Shah S.A., Copeland P., Omar G., and Winfield A. Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. Br J Dermatol 152 4 (2005) 758-764
36. Simpson D., and Curran M.P. Temsirolimus: in advanced renal cell carcinoma. Drugs 68 5 (2008) 631-638
37. Dunn C., and Croom K.F. Everolimus: a review of its use in renal and cardiac transplantation. Drugs 66 4 (2006) 547-570
38. Lorber M.I., Mulgaonkar S., Butt K.M., Elkhammas E., Mendez R., Rajagopalan P.R., et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 80 2 (2005) 244-252
39. Bottiger Y., Sawe J., Brattstrom C., Tollemar J., Burke J.T., Hass G., et al. Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. Clin Pharmacol Ther 69 1 (2001) 32-40